Effect of sunitinib on platelet function


Protocolnummer:
16-4-270

Ziekenhuizen:
Maastricht UMC+

Titel:

Effect of sunitinib on platelet function

To investigate whether platelet count and activation can be used to monitor sunitinib pharmacodynamics and response to therapy.

Behandeling:
Sunitinib. To investigate whether platelet count and activation can be used to monitor sunitinib pharmacodynamics and response to therapy.

Stadium:

Belangrijkste in/exclusiecriteria:

  • Inclusie criteria:
    • Patients (men or women) with histologically proven renal cell cancer who are starting treatment with sunitinib
    • > 18 years
    • Hb >5.6 mmol/L
  • Exclusie criteria:
    • Patients with known genetic abnormalities affecting platelet function and coagulation
    • Patients who received anti-platelet medication during the study or 14 days before the onset of the study
    • Patients who have received blood or platelet transfusion during the study or 14 days before the onset of the study
    • Patients who have a diagnosed active infection, ulcers and/or non-healing wounds.
    • Patients who are pregnant or breastfeeding
    • Active thrombosis

Contactpersoon:
Marijke J.E. Kuijpers, PhD: Marijke.Kuijpers@maastrichtuniversity.nl
Maureen J. Aarts, MD, PhD: mjb.essers.aarts@mumc.nl

Alle niercelcarcinoom trials